Cargando…

c-Fos over-expression promotes radioresistance and predicts poor prognosis in malignant glioma

c-Fos is a major component of activator protein (AP)-1 complex. It has been implicated in cell differentiation, proliferation, angiogenesis, invasion, and metastasis. To investigate the role of c-Fos in glioma radiosensitivity and to understand the underlying molecular mechanisms, we downregulated c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhi-Gang, Jiang, Guanmin, Tang, Jiao, Wang, Hui, Feng, Guokai, Chen, Furong, Tu, Ziwei, Liu, Guiyun, Zhao, Yu, Peng, Ming-Jing, He, Zheng-Wen, Chen, Xiao-Yan, Lindsay, Holly, Xia, Yun-Fei, Li, Xiao-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323205/
https://www.ncbi.nlm.nih.gov/pubmed/27602752
http://dx.doi.org/10.18632/oncotarget.11779
Descripción
Sumario:c-Fos is a major component of activator protein (AP)-1 complex. It has been implicated in cell differentiation, proliferation, angiogenesis, invasion, and metastasis. To investigate the role of c-Fos in glioma radiosensitivity and to understand the underlying molecular mechanisms, we downregulated c-Fos gene expression by lentivirus-mediated shRNA in glioma cell lines and subsequently analyzed the radiosensitivity, DNA damage repair capacity, and cell cycle distribution. Finally, we explored its prognostic value in 41 malignant glioma patients by immunohistochemistry. Our results showed that silencing c-Fos sensitized glioma cells to radiation by increasing radiation-induced DNA double strand breaks (DSBs), disturbing the DNA damage repair process, promoting G2/M cell cycle arrest, and enhancing apoptosis. c-Fos protein overexpression correlated with poor prognosis in malignant glioma patients treated with standard therapy. Our findings provide new insights into the mechanism of radioresistance in malignant glioma and identify c-Fos as a potentially novel therapeutic target for malignant glioma patients.